Heron Therapeutics traded at $4.01 this Thursday September 29th, decreasing $0.48 or 10.69 percent since the previous trading session. Looking back, over the last four weeks, Heron Therapeutics lost 2.30 percent. Over the last 12 months, its price fell by 62.49 percent. Looking ahead, we forecast Heron Therapeutics to be priced at 3.86 by the end of this quarter and at 3.53 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 7,640.00 -64.00 -0.83% -6.69%
Alnylam Pharmaceuticals 209.39 -1.37 -0.65% 10.90%
Amarin 1.10 -0.09 -7.56% -78.43%
Anika Therapeutics 23.41 -1.16 -4.72% -45.00%
ANI Pharmaceuticals 31.63 -0.56 -1.74% -3.63%
Arrowhead Research 33.28 -0.68 -2.00% -46.69%
Endo International 0.10 -0.003 -2.76% -96.84%
GlaxoSmithKline 1,315.80 -25.80 -1.92% -6.26%
Heron Therapeutics 4.01 -0.48 -10.69% -62.49%
Immunogen 4.70 -0.01 -0.21% -17.11%
Insmed 21.87 -0.91 -3.99% -20.59%
Jazz Pharmaceuticals 132.42 3.48 2.70% 1.70%
Ligand Pharmaceuticals 85.57 0.38 0.45% -38.58%
Merck & Co 86.64 -0.14 -0.16% 15.35%
Neurocrine Biosciences 102.76 -0.07 -0.07% 7.14%
Nektar Therapeutics 3.04 -0.17 -5.30% -83.07%
Omeros 3.22 -0.25 -7.20% -76.65%
Pacira 54.24 0.10 0.18% -3.14%
Ultragenyx Pharmaceutical 40.55 -0.72 -1.74% -55.04%
Regeneron Pharmaceuticals 691.82 -13.60 -1.93% 21.20%
Roche Holding 320.25 -5.20 -1.60% -6.35%
Surmodics 30.34 0.05 0.17% -45.43%
Teva Pharmaceutical Industries 7.82 -0.14 -1.76% -19.71%
Veracyte 16.64 -0.76 -4.37% -64.18%
Vertex Pharmaceuticals 292.80 0.39 0.13% 62.35%
Sangamo BioSciences 4.87 -0.34 -6.53% -45.95%
Esperion Therapeutics 6.84 -0.47 -6.43% -43.24%
Emergent BioSolutions 20.78 -0.55 -2.58% -58.50%
ALKERMES 22.46 -0.47 -2.05% -27.17%

Indexes Price Day Year
USND 10738 -314.13 -2.84% -25.68%
US2000 1675 -40.31 -2.35% -24.02%

Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.